Skip to main content
CELC
NASDAQ Industrial Applications And Services

Celcuity Q3 Loss Widens to $73.3M as REVTORPYK Launch Begins; $642.7M Cash Funds Through 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$64.04
Mkt Cap
$3.134B
52W Low
$53.54
52W High
$151.02
52W Position info
20% above low
Off High info
58% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CELC sits 20% above its 52-week low of $53.54.

Summary

Celcuity's Q3 loss widened to $73.3 million ($1.33/share) on launch spending, with no product revenue yet since REVTORPYK shipped only on September 30. Cash of $642.7 million is expected to fund operations through 2029.


Key Events · Earnings and Guidance · CELC

  • Q3 Loss Widens on Launch Spend

    Net loss was $73.3 million, or $1.33 per share, versus $43.8 million, or $0.92 per share, a year earlier. Non-GAAP adjusted net loss was $66.8 million, or $1.21 per share.

  • No Product Revenue Booked Yet

    REVTORPYK shipments began September 30, 2026, so no product was delivered to providers or pharmacies before quarter-end and no revenue was recognized. Q4 is the first quarter with a real top line.

  • Launch Metrics Show Early Traction

    91% of U.S. commercial and Medicare lives are in plans covering REVTORPYK, and 78% of the top 36 strategic accounts — about 50% of the addressable patient population — have ordered. Over 3,400 sites have engaged with sales specialists.

  • Cash of $642.7M Funds Through 2029

    Cash, cash equivalents and short-term investments were $642.7 million at September 30, 2026, against $66.2 million of quarterly operating cash burn and a $50.0 million Pfizer approval milestone payment.


Analysis · CELC · Industrial Applications And Services

The headline loss is $73.3 million, or $1.33 per share, against $43.8 million a year ago, driven by a $27.4 million jump in SG&A as Celcuity built out the sales force for its first commercial product. More important is the top line that isn't there yet: no product revenue was booked in the quarter because REVTORPYK shipments only started September 30, so Q4 is the first quarter that will show whether the launch is real. Early indicators are constructive, with 91% of U.S. commercial and Medicare lives covered and 78% of the top 36 accounts, roughly half the addressable population, having already ordered. With $642.7 million in cash and a stated runway through 2029, the company does not need to raise money to fund this launch, which removes the near-term dilution risk that hangs over most commercial-stage biotechs. The offset is a $754.0 million convertible note balance that leaves stockholders' equity at a $74.0 million deficit.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELC was trading at $64.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $53.54 to $151.02. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELC - Latest Insights

CELC
Nov 09, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $66.32
Real-time Price: $54.73 info
Change: -$11.59 (-17%) info
Market Cap: $2.689B info
CELC
Nov 05, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $54.73 info
Change: -$9.31 (-15%) info
Market Cap: $2.689B info
CELC
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $64.04
Real-time Price: $54.73 info
Change: -$9.31 (-15%) info
Market Cap: $2.689B info
CELC
Sep 30, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.00
Real-time Price: $54.73 info
Change: -$24.27 (-31%) info
Market Cap: $2.689B info
CELC
Aug 26, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $91.00
Real-time Price: $54.73 info
Change: -$36.27 (-40%) info
Market Cap: $2.689B info